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Background: The miR-9 family microRNAs have been identified as a tumor suppressor miRNA in cancers. We
postulated that miR-9-1, miR-9-2 and miR-9-3 might be inactivated by DNA hypermethylation in chronic
lymphocytic leukemia (CLL).
Methods: Methylation of miR-9-1, miR-9-2 and miR-9-3 was studied in eight normal controls including normal bone
marrow, buffy coat, and CD19-sorted peripheral blood B-cells from healthy individuals, seven CLL cell lines, and
seventy-eight diagnostic CLL samples by methylation-specific polymerase chain reaction.
Results: The promoters of miR-9-3 and miR-9-1 were both unmethylated in normal controls, but methylated in five
(71.4%) and one of seven CLL cell lines respectively. However, miR-9-2 promoter was methylated in normal controls
including CD19 + ve B-cells, hence suggestive of a tissue-specific but not tumor-specific methylation, and thus not
further studied. Different MSP statuses of miR-9-3, including complete methylation, partial methylation, and
complete unmethylation, were verified by quantitative bisulfite methylation analysis. 5-Aza-2′-deoxycytidine
treatment resulted in miR-9-3 promoter demethylation and re-expression of pri-miR-9-3 in I83-E95 and WAC3CD5+
cells, which were homozygously methylated for miR-9-3. Moreover, overexpression of miR-9 led to suppressed cell
proliferation and enhanced apoptosis together with downregulation of NFκB1 in I83-E95 cells, supporting a tumor
suppressor role of miR-9-3 in CLL. In primary CLL samples, miR-9-3 was detected in 17% and miR-9-1 methylation
in none of the patients at diagnosis. Moreover, miR-9-3 methylation was associated with advanced Rai stage
(≥ stage 2) (P = 0.04).
Conclusions: Of the miR-9 family, miR-9-3 is a tumor suppressor miRNA relatively frequently methylated, and hence
silenced in CLL; whereas miR-9-1 methylation is rare in CLL. The role of miR-9-3 methylation in the constitutive
activation of NFκB signaling pathway in CLL warrants further study.
Keywords: microRNA, miR-9-3, Tumor suppressor, DNA methylation, NFκB, Chronic lymphocytic leukemiaIntroduction
DNA methylation refers to the chemical modification of
the cytosine ring in a CpG dinucleotide by the addition of
a methyl group (-CH3) to the number 5 carbon of the
cytosine pyrimidine ring in the CpG dinucleotide, result-
ing in the formation of 5-methylcytosine [1]. Global
DNA hypomethylation, but aberrant, gene-specific DNA* Correspondence: jcschim@hku.hk
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of tumor suppressor genes (TSGs), is a hallmark of many
human cancers [2,3]. Methylation of multiple TSGs has in-
volved in the dysregulation of signaling pathways in
leukemia, lymphoma and myeloma, including cell cycle
(CDKN2A/B), apoptosis (DAPK1/CDKN2A/APAF1), JAK/
STAT signaling and WNT signaling; thereby indicating the
importance of TSGs methylation in the pathogenesis of
hematological cancers [4-6]. Of note, the DNA hyperme-
thylation in TSGs, such as DAPK1, ID4, SFRP1, TWIST2
and ZAP70, has been identified to play a role in thetd. This is an open access article distributed under the terms of the Creative
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leukemia (CLL) [7-11].
Mature microRNA (miRNAs) are endogenous, single-
stranded, non-protein-coding small RNAs measuring 19
to 25 nucleotides (nts), which suppress the expression of
proteins that they target [12,13]. In carcinogenesis, miR-
NAs can be categorized into either oncogenic (onco-
mirs) or tumor suppressor miRNAs [14,15]. Recently,
tumor suppressor miRNAs have shown to be silenced by
aberrant DNA hypermethylation in cancers [1,16,17].
Furthermore, previous studies also identified methyla-
tion of some tumor suppressor miRNAs, including miR-
203, miR-124-1, miR-181a/b, miR-107 and miR-424, to
be involved in CLL leukemogenesis [18].
In humans, there are three independent miR-9 genes
(miR-9-1 on chromosome 1; miR-9-2 on chromosome 5
and miR-9-3 on chromosome 15), with identical mature
miR-9 sequence. In cancers, miR-9 could be either onco-
mir or tumor suppressor miRNA, depending on the type
of cancers or tissues [19,20]. For instance, overexpres-
sion of miR-9 has been shown to enhance metastasis or
invasion in breast cancer cells or glioblastoma, identify-
ing its oncogenic role [21-23]. Conversely, miR-9 has
been shown to target and repress NFκB1 translation in
ovarian tumor cells by binding to the 3′ untranslated re-
gion (3′ UTR) of the NFκB1 mRNA, leading to inhib-
ition of cell proliferation; hence demonstrating a tumor
suppressor function [24].
In this report, we studied methylation of miR-9-3, in
addition to miR-9-1 and miR-9-2 in a representative co-
hort of CLL to define its pathogenetic role.
Materials and methods
Patient samples
Bone marrow samples were obtained from 78 CLL patients
at diagnosis. The diagnosis of CLL was made according to
the WHO Classification, based on classical morphology,
low level of expression of light-chain-restricted surface im-
munoglobulin, and concomitant expression of CD5 and
CD23 as demonstrated by flow cytometry [25,26]. Of the
78 CLL patients, there were 51 male (65.4%) and 27 female
(34.6%) patients at a median age of 65 years (range: 37–91
years). The median presenting lymphocyte count was 18 ×
109/L (range: 10–540 × 109/L). Apart from 8 patients with
insufficient Rai stage data, there were 42 (60.0%) limited
Rai stage (<stage II) and 28 (40.0%) advanced Rai stage
(≥stage II) patients. Among the 53 patients with cytogen-
etic information, 13 (24.5%) carried high/intermediate-risk
cytogenetic aberrations [del(17p), N = 2; del(11q), N = 2;
trisomy 12, N = 9] and 40 (75.5%) carried low/standard-risk
cytogenetic alterations [del(13q), N = 12; normal karyotype,
N = 21; other karyotypic changes, N = 7]. The median over-
all survival (OS) of this cohort was 69 months. The median
OS of those with advanced Rai stage and limited Rai stagewere 49 and 111 months respectively (P = 0.006). Further-
more, the median OS for those with or without high/inter-
mediate-risk karyotype were 28 months and 111 months
respectively (P = 0.003). Samples were obtained with writ-
ten informed consent, and the study was approved by the
Institutional Review Board of Queen Mary Hospital and in
accordance with the Declaration of Helsinki.
Cell lines and culture
The human CLL cell lines CLL-AAT and MEC1 were pur-
chased from American Type Culture Collection (Manassas,
USA) and Deutsche Sammlung von Mikroorganismen und
Zellkulturen Deutsche GmbH (DMSZ) (Braunschweig,
Germany) respectively. MEC2, I83-E95 and WAC3CD5+
were kindly provided by Dr John C. Byrd, Department of
Medicine, Ohio State University [27,28]. HG3 and 232B4
were kind gifts from Prof. Anders Rosén, Department of
Clinical & Experimental Medicine, Linköping University
[28,29]. Cell cultures were maintained in RPMI medium
1640, supplemented with 10% fetal bovine serum, 50 U/ml
penicillin, and 50 μg/ml streptomycin (Invitrogen, Carlsbad,
CA, USA) in a humidified atmosphere of 5% CO2 at 37°C.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from seventy-eight bone marrow
samples of CLL at diagnosis, seven cell lines and eight
normal controls (CD19 sorted peripheral blood B cells
from healthy donors, N = 3; peripheral blood buffy
coats from healthy donors, N = 2; and bone marrow
buffy coats from healthy donors, N = 3) by the QIAamp
DNA Blood Mini Kit (QIAGEN, Germany). The MSP
for aberrant gene promoter methylation was performed
as described in detail previously [30]. Each sample was
amplified with two sets of primers, one set for methylated
DNA (methylated MSP) and one set for unmethylated
DNA (unmethylated MSP). Treatment of DNA with
bisulfite for conversion of unmethylated cytosine to
uracil (but unaffecting methylated cytosine) was per-
formed with the EpiTect Bisulfite Kit kit (QIAGEN,
Germany). Details of primers and conditions for MSP
of miR-9-1, miR-9-2 and miR-9-3 were given in
Additional file 1: Table S1.
Quantitative bisulfite pyrosequencing
DNA was treated with bisulfite and used as template.
Primers for pyrosequencing were used to amplify the pro-
moter region, which was overlapped with the amplicon of
MSP. Primers were designed using PSQ Assay Design soft-
ware (Biotage). Forward primer: 5′-GAAGGGGGTTGG
GATTTGA-3′; Reverse primer: 5′-ATTTCTCCCCTACT
CCCC-3′; condition: 2mM/61°C/50X. A stretch of DNA
with 9 adjacent CpG dinucleotides was pyrosequenced by
sequencing primer: 5′-ATGGGAGTTTGTGAT-3′.
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I83-E95 and WAC3CD5+ cells at log-phase were cultured
in six-well plates at a density of 1 × 106 cells/ml, with
0.5 μM of 5-AzadC (Sigma-Aldrich, St. Louis, MO, USA)
for 5 days respectively, as described [31]. Fresh 5-AzadC
was replaced every 24 hours. I83-E95 and WAC3CD5+
cells on day 0 and day 5 of 5-AzadC treatment were har-
vested respectively.
Quantification of pri-miR-9-3 and miR-9
According to the manufacturer’s instructions, total RNA
was isolated using the mirVana miRNA Isolation Kit
(Ambion, Austin, TX, USA). For quantification of pri-
miR-9-3, miRNA was reversely transcribed by the Quan-
tiTect Reverse Transcription Kit (QIAGEN, Valencia,
CA), and quantified using the TaqMan Pri-miRNA Assay
(ABI, Foster City, CA). GAPDH was used as reference
for data analysis using the 2-ΔΔCT method [32]. More-
over, miR-9 was quantified by the TaqMan MicroRNA
RT Kit, and TaqMan MicroRNA Assay Kit. RNU48 was
chosen as reference using the 2-ΔΔCT method [32].
Overexpression of miR-9 precursor
According to the manufacturers’ instructions, precursor
miR-9 mimic (final concentration 100 nM) (Ambion,
Austin, TX, USA) was transfected into 1 × 106 I83-
E95 cells and WAC3CD5+ cells respectively, using X-
tremeGENE siRNA Transfection Reagent (Roche, Basel,
Switzerland), as described [33]. Non-targeting oligo-
nucleotide mimic was used as the negative control.
Cell proliferation, viability analyses
The MTT method was used to determine cellular prolif-
eration [34]. Cells were seeded in a 96-well microtitre
plate at 2.5 × 104/well in 100 μl of medium. At the assay
test time point 48 hours after transfection, 10 μl of 5
mg/ml MTT reagent was added to each well and incu-
bated for 4 hours. Then each well was added with 100 μl
dimethyl sulfoxide (DMSO), followed by the measure-
ment of absorbance at 550 nm with reference to 650
nm. Cellular viability assay was performed by the Trypan
blue dye exclusion assay under microscope. Dead cells
(%) = (total number of dead cells per microscopic field/
total number of cells per microscopic field) × 100. Five
random microscopic fields were counted in each sample.
Cellular apoptosis analysis
Cell apoptosis was assessed by flow cytometry using
FITC Annexin V and PI staining as described previously
[35]. FITC Annexin V Apoptosis Detection Kit I (BD-
Pharmingen) was used here. 1 × 106 I83-E95 or
WAC3CD5+ cells were washed with cold PBS and resus-
pended in 100 μl binding buffer with 5 ul of Annexin V
and 5 ul PI, and then incubated for 15 minutes at roomtemperature in the dark. After adding 400 μl binding
buffer to each tube, samples were analyzed by flow cy-
tometry (BD FACS Canto II). FITC Annexin V positive,
PI negative or FITC Annexin V positive, PI positive cells
were counted as apoptosis cells.
Western blot for NFκB1
After 48 hours transfection, I83-E95 cells were harvested
and lysed in RIPA buffer (50 mM Tris- HCl, pH 7.4, 150
mM NaCl, 0.2% SDS, 1% Triton X-100, 2 mM EDTA).
Protein lysates were separated on 10% SDS-PAGE and
blotting were performed on a 0.2 μm nitrocellulose
membrane (Bio-Rad, Hercules, CA). The membranes
were incubated with NFκB1 (1:1000; Santa Cruz, CA) or
anti-actin (1:5000; Sigma-Aldrich, USA) primary anti-
body at 4°C overnight. Then membranes were washed
and incubated with anti-rabbit horseradish peroxidase
conjugate secondary antibody at room temperature for 1
hour. Protein signals were detected by ECL plus West-
ern blotting detection reagents (Amersham Biosciences,
Buckinghamshire, UK) and exposed to X-ray film.
Statistical analysis
In CLL, the association of miR-9-3 methylation status
with continuous variables (such as mean age, mean
lymphocyte counts, diagnostic hemoglobin or platelet
counts) and categorical variables (gender, Rai stage or
high-risk karyotypes) were analyzed by student’s t-test
and chi-square test (or Fisher’s exact test) respectively.
OS is assessed from the date of diagnosis to the date of
last follow-up or death. OS of patients with limited Rai
stage (stages 0, I and II) was compared with those with
advanced Rai stage (stages III and IV). Furthermore, OS
of patients with high-risk karyotypes [del(17p), del(11q)
or trisomy 12] was compared to those with standard-risk
karyotypes [del(13q), normal karyotype or other karyo-
typic changes]. The mean values of MTT assay, Trypan
blue exclusion assay, FITC Annexin V and PI staining
apoptosis analysis in I83-E95 or WAC3CD5+ cells trans-
fected with precursor miR-9 mimic were compared to
those transfected with the scrambled oligo by student’s
t-test. Survival was plotted by the Kaplan–Meier method





None of the 8 normal controls (N1 to N8) showed aber-
rant methylation of miR-9-3 and miR-9-1 (Figure 1A).
Expected MSP results (normal DNA: U-MSP positive/
M-MSP negative; methylated DNA: U-MSP negative/M-
MSP positive) were obtained in the positive and negative
controls. Moreover, direct sequencing of the miR-9-3
Figure 1 Methylation of miR-9-3 and miR-9-1 in controls. A, U- and M-MSP of miR-9-3 and miR-9-1 showed that the positive control (PC) was
completely methylated while all 8 normal controls (N1-N8) were completely unmethylated. B, Sequence analysis of the miR-9-3 and miR-9-1 M-
MSP product from bisulfite-treated positive control DNA respectively showed that the cytosine (C) residues of CpG dinucleotides were methylated
and remained unchanged, whereas all the other C residues were unmethylated and were converted to thymidine [T], suggesting complete bisul-
fite conversion and specificity of MSP. MW: Marker; B: Reagent blank; N1 to N3: CD19 sorted B cells of the peripheral blood from healthy donors;
N4 to N5: peripheral blood buffy coat from healthy donors; N6 to N8: normal bone marrow control; PC: positive control with methylated DNA.
Figure 2 Methylation of miR-9-3 and miR-9-1 in CLL cell lines. A, In
CLL cell lines, I83-E95 and WAC3CD5+ were completely methylated,
232B4, CLL-AAT and HG3 were heterozygously methylated while MEC1
and MEC2 were completely unmethylated for miR-9-3. B, In CLL cell
lines, I83-E95 was completely methylated while the other cell lines were
completely unmethylated for miR-9-1. C1:MEC1; C2:MEC2; C3:232B4; C4:
CLL-AAT; C5:HG3; C6:I83-E95; C7:WAC3CD5+. MW: Marker; B: Reagent
blank; N1: Normal donor; PC: Positive control with methylated DNA.
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positive control showed the expected nucleotide
changes, confirming complete bisulfite conversion and
specificity of MSP (Figure 1B). However, the normal
controls including normal CD19 + ve B-cells showed
methylation of miR-9-2 (Additional file 1: Figure S1A),
which was confirmed by direct sequencing (Additional
file 1: Figure S1B). Therefore, methylation of miR-9-2
was not further studied.
CLL cell lines
The profile of miR-9-3 methylation of seven CLL cell
lines was shown in Figure 2A. I83-E95 and WAC3CD5+
cell lines showed complete methylation of miR-9-3,
232B4, CLL-AAT and HG3 partial methylation while
MEC1 and MEC2 were completely unmethylated. Quan-
titative bisulfite pyrosequencing confirmed the methyla-
tion statuses (MM, MU, UU) of CLL cell lines detected
by MSP (Additional file 1: Table S2 and Figure S2A-C).
Moreover, apart from I83-E95, in which miR-9-1 was
completely methylated, in MEC1, MEC2, 232B4, CLL-
AAT, HG3 and WAC3CD5+, miR-9-1 was completely
unmethylated (Figure 2B).
Primary samples at diagnosis
Methylation of miR-9-3 was found in thirteen of seventy-
eight (17%) patient samples at diagnosis (Figure 3A), whilemiR-9-1 methylation was not detected in any of CLL pa-
tients (Figure 3B). There was no significant correlation be-
tween miR-9-3 methylation and the diagnostic hemoglobin
level (P = 0.14), lymphocyte count (P = 0.07), age (P = 0.83),
gender (P = 0.36) or high-risk karyotypes (P = 0.67).
Figure 3 Promoter methylation of miR-9-3 and miR-9-1 in CLL
primary samples. U-/M-MSP analysis of (A) miR-9-3 and (B) miR-9-1
methylation in CLL primary samples. MW: Marker; B: Reagent blank;
N1: Normal donor; S: Sample at diagnosis; PC: Positive control with
methylated DNA.
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with platelet count (P = 0.03) and advanced Rai stage
(≥ stage 2) (P = 0.04) was found. The mean OS of CLL pa-
tients with and without miR-9-3 methylation were 103 and
87 months respectively (P = 0.72).
5-AzadC treatment of I83-E95 and WAC3CD5+ cells
I83-E95 and WAC3CD5+ cells were completely methylated
for miR-9-3. 5-AzadC treatment of I83-E95 and WAC3CD5
+ cells resulted in demethylation of miR-9-3 and the emer-
gence of U-MSP signal on day 5 respectively (Figure 4;Figure 4 Effect of 5-Aza-2′-deoxycytidine (5-AzadC) treatment on I83-
methylation status and stem-loop RT-qPCR analysis of the pri-miR-9-3 expre
with 0.5 μM 5-Azad C for 5 days. ΔCt, Ct pri-miR-9-3-Ct GAPDH. GAPDH wa
method. 5-AzadC treatment led to the progressive demethylation of miR-9
WAC3CD5+ cells. Columns represent mean ± standard deviation of triplicaAdditional file 1: Figure S2D), with the re-expression of pri-
miR-9-3 as shown by TaqMan stem-loop quantitative RT-
PCR (Figure 4).
Effect of miR-9 overexpression in I83-E95 cells and
WAC3CD5+ cells
Complete methylation of miR-9-3 was found for the I83-
E95 cells and WAC3CD5+ cells, leading to its under ex-
pression. Upon transfection of precursor miR-9 mimic into
I83-E95 cells, overexpression of miR-9 was demonstrated
by TaqMan stem-loop quantitative RT-PCR at 48 hours
after transfection (Figure 5A). Compared with the negative
control transfected with a scrambled oligo at 48 hours,
cells overexpressing miR-9 mimic showed a 26% reduction
of cellular proliferation by MTTassay (P = 0.02, Figure 5B),
a 12% increase of dead cells measured by Trypan blue ex-
clusion assay (P = 0.03, Figure 5C) and a 13% increase of
apoptosis cells by FITC Annexin V and PI staining (P =
0.02, Figure 5D). Similarly, miR-9 mimics reexpression in
WAC3CD5+ cells also led to the inhibition of cell prolifer-
ation and increase of cell apoptosis (Additional file 1:
Figure S3), indicating that miR-9-3 played a tumor sup-
pressive role in CLL cells. Moreover, miR-9 overexpression
in I83-E95 cells led to the downregulation of NFκB1
protein, including the 46% decrease of the cytoplasmic pre-
cursor P105 and 42% decrease of the corresponding pro-
cessing product P50 respectively (Figure 5E).
Discussion
Despite the retrospective nature, this cohort of patients
had previously been shown to be typical of CLL, in thatE95 and WAC3CD5+ cells. U-/M-MSP analysis of miR-9-3 promoter
ssion in untreated (A) I83-E95, (B) WAC3CD5+ cells and after treatment
s used as reference for data analysis of pri-miR-9-3 expression by 2-ΔΔCT
-3 promoter, and re-expression of the pri-miR-9-3 in I83-E95 and
te qPCRs.
Figure 5 Overexpression of miR-9 in CLL cells. I83-E95 cells, completely methylated for miR-9-3, were transfected with miR-9 mimic or scrambled
control oligo. Cells were harvested for functional assays 48 hours after transfection. A, Stem-loop RT-qPCR analysis of miR-9 expression at 48 hours
after transfection. ΔCt, Ct miR-9-Ct RNU48. RNU48 was chosen as reference using the 2-ΔΔCT method. B, Cell proliferation of CLL cells in response
to overexpression of miR-9 was measured by MTT assay. Column, mean percentage of cell proliferation from three experiments conducted in triplicate;
C, Cellular death was measured by Trypan blue exclusion assay. Column, mean percentage of cell death from three experiments conducted in
triplicate; D, Cell apoptosis of CLL cells after miR-9 transfection was assessed by flow cytometry using FITC Annexin V and PI staining (left panel:
representative result; right panel: values represented mean percentage of cell apoptosis from three experiments performed in triplicate. E,
Western blot analysis of NFκB1 (P105/P50) after miR-9 transfection. Total protein was extracted 48 hours after transfection and membranes were
probed with antibodies to P105, P50 and Anti-actin. Anti-actin protein was regarded as the endogenous normalizer and the relative NFκB1
(P105/P50) protein level was shown. Error bars represent standard deviation.
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vival, which was adversely impacted by advanced Rai
stage and high-risk karyotypes.
Firstly, miR-9-3 and miR-9-1 methylation in CLL cell
lines was tumor-specific as evidenced by the absence of
methylation in normal peripheral blood buffy coat and
CD19-sorted B-cells, and normal bone marrow cells. By
contrast, miR-9-2 methylation appeared to occur both in
normal CD19 + ve B-cells and CLL B-cells, and hencethis pattern of methylation is tissue-specific but not
tumor-specific [36]. Similarly, miRNAs such as miR-127
and miR-373 have been shown hypermethylated in both
normal and tumor cells, and hence represent tissue-
specific but not tumor-specific miRNA methylation [36].
On the other hand, a recent study of miRNAs deregu-
lated by either gene hypo- or hyper-methylation in CLL
showed methylation of miR-9-2 in CLL [37]. This dispar-
ity might be accounted by the use of quantitative
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tion of miR-9-2 was defined as a certain level of methy-
lation above that occurring in normal controls. However,
as Chinese have a much lower incidence of CLL,
whether miR-9-2 methylation in Caucasian patients
arose from a primary biological difference between the
Asian and Western could not be excluded [38,39].
Furthermore, upon the 5-AzadC treatment of I83-E95
and WAC3CD5+ cells, both of which were homozy-
gously methylated for miR-9-3, emergence of U-MSP
signal, and thus demethylation of miR-9-3 promoter, was
correlated with pri-miR-9-3 re-expression. Therefore,
miR-9-3 methylation is frequent in CLL cell lines, lead-
ing to the reversible miRNA silencing.
Moreover, tumor suppressor activity of miR-9-3 was
demonstrated in CLL. We showed that restoration of
miR-9 in I83-E95 cells harboring complete methylation
of miR-9-3 led to reduced cellular proliferation and en-
hanced apoptosis. In addition, overexpression of miR-9
led to downregulation of NFκB1 (P105/P50), consistent
with previous data that NFκB1 was a direct target of
miR-9 by translational repression in ovarian cancer cells
[24]. On the other hand, while the tumor suppressor role
of miR-9, due to epigenetically downregulation, has been
reported in some cancers [19,40-43]. miR-9 has also
been implicated as an oncomir in other cancers. For ex-
ample, in breast cancer cells, as a metastasis-promoting
miRNA, miR-9 led to enhanced cell motility and hence
invasiveness by targeting E-cadherin [21]. In glioblast-
oma cells, overexpression of miR-9/9* could inhibit the
expression of the tumor suppressor gene CAMTA1,
leading to enhanced cell survival, implying that it might
be an oncomir [23].
Interesting, we noted the significant association of
miR-9-3 methylation with advanced Rai stage (≥ stage 2)
in CLL patients, which is a poor risk factor for survival.
Similarly, miR-9-3 methylation has been shown to be as-
sociated with metastatic recurrence in renal cell carcin-
oma [40], in addition to shorter disease-free and overall
survivals in squamous cell lung cancer [41]. However,
apart from Rai stage, there was no association between
the miR-9-3 methylation and other clinical parameters
including age, gender, diagnostic hemoglobin, lympho-
cyte counts, high-risk karyotypic aberrations or survival.
Given the small number of samples in our cohort, the
possible role of miR-9-3 as a prognostic marker by
impacting on survival requires validation in a larger scale
study.
Constitutive activation of NFκB have played roles in car-
cinogenesis, including stimulating cell proliferation, inhi-
biting cell apoptosis and increasing tumor metastasis [44].
Upon canonical NFκB activation by cytokines such as IL-
1, IL-2 or TNFα, NFκB (a dimer comprising P50:P65) is
released from the NFκB-IκBα complex, allowing nucleartranslocation of NFκB and signaling activation [45,46].
NFκB1 gene encodes 2 functional proteins, the cytoplas-
mic precursor P105 and the corresponding processed
product P50. In HEK-293 cells and ovarian cancer ES-2
cells, NFκB1 has been shown to be a direct target of miR-9
by luciferase assay [24,47]. Moreover, miR-9 overexpres-
sion suppressed tumor cell proliferation in association
with repression of NFκB pathway, thereby confirming the
tumor suppressive role of miR-9 via the regulation of
NFκB signaling in ovarian cancer [24]. Similarly, constitu-
tive activation of NFκB activity has been demonstrated in
CLL cells, conferring survival benefit through induction of
a multitude of anti-apoptotic proteins including X-linked
inhibitor of apoptosis protein (XIAP), FLICE-like inhibi-
tory protein (FLIP) and members of the BCL2 family
(BCL-XL and A1/BFL1) [48,49]. In our study, we also
showed that miR-9 overexpression in I83-E95 cells re-
sulted in downregulation of NFκB1 (P105/P50) protein.
Therefore, miR-9-3 methylation may account for constitu-
tive upregulation of NFκB1, and hence constitutive NFκB
activation in CLL patients.
Conclusions
Taken together, our results revealed that miR-9-3 was a
tumor suppressor miRNA frequently methylated in CLL.
miR-9-3 was a tumor suppressor miRNA hypermethy-
lated in CLL, which was associated with down-regulation
of NFκB1 protein, and hence might contribute to
constitutive activation of NFκB signaling pathway in
CLL.
Additional file
Additional file 1: Figure S1. Methylation of miR-9-2 in controls. (A).
M-MSP of miR-9-2 showed that the positive control (PC) and 3 normal
CD19 + ve B-cell controls (N1-N3) were completely methylated (B).
Sequence analysis of the miR-9-2 M MSP product from bisulfite treated
PC DNA and 3 normal CD 19 + ve B cell controls showed that in normal
controls, the cytosine (C) residues of partial CpG dinucleotides were
methylated compared with the PC sequence. (C). Schematic diagram to
display the six CpG dinucleotides illustrated in the sequence. PC showed
methylated (black box) of all six CpGs, while normal CD19 + ve B-cell
control (1-3) displayed partially miR-9-2 methylation. Table S1: miR-9-1,
miR-9-2 and miR-9-3 MSP Primer sequences and the reaction condition.
Table S2: Average percent methylation for miR-9-3 in 7 CLL cell lines by
pyrosequencing. Figure S2: Quantitative bisulfite pyrosequencing
analysis of miR-9-3. The pyrograms showed the methylation intensity on
a stretch of 9 neighboring CpG dinucleotides of (A) Normal control
without methylation and positive control with methylated DNA, (B-C)
CLL cell lines with defined MSP methylation status (MM, MU and UU)
and (D) WAC3CD5+ cells before and after 5-azadC treatment. Figure
S3: Overexpression of miR-9 in WAC3CD5+ cells. WAC3CD5+ cells,
completely methylated for miR-9-3, which were transfected with miR-9
mimic or scrambled control oligo. (A). miR-9 expression at 48 hours after
transfection was measured by Stem-loop RT-qPCR analysis. (B). Cell
proliferation of CLL cells in response to overexpression of miR-9 was
assessed by MTT assay, whereas (C) cellular death was measured by
Trypan blue exclusion assay and (D) the percentage of apoptosis CLL
cells was assessed by flow cytometry using FITC Annexin V and PI
staining. Error bars represents standard deviation.
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